This article is more than 5 years old. Information may no longer be current.
New study further validates Cellvizio for diagnosing pancreatic cysts
Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy using the Cellvizio platform was effective for optical biopsy of pancreatic cysts, supporting its use as an imaging biomarker in pancreatic cyst diagnosis, according to new research.
“This new peer-reviewed study ... provides further validation of the application of Cellvizio [Mauna Kea Technologies] needle-based CLE in the diagnosis of pancreatic cysts,” Sacha Loiseau, PhD, founder and CEO of Mauna Kea Technologies, said in a press release. “There is a significant opportunity for clinicians to use optical biopsy with Cellvizio in the often-challenging task of diagnosing pancreatic cysts, allowing them to make faster diagnoses and better treatment decisions to achieve better outcomes for their patients.”
In a prospective study, Somashekar Krishna, MBBS, MPH, and researchers from the division of gastroenterology, hepatology and nutrition at the Wexner Medical Center at The Ohio State University, sought to determine if in vivo nCLE patterns could be reproduced in an ex vivo setting, and compared these findings to surgical histopathology. To do so, they evaluated 10 patients (mean age, 53 years; 50% men) who underwent in vivo nCLE and ex vivo probe-based CLE of their surgically resected pancreatic cystic lesions.
Surgical histopathology confirmed two intraductal papillary mucinous neoplasms, three mucinous cystic neoplasms, two cystic neuroendocrine tumors, one serious cystadenoma, and two squamous lined pancreatic cystic lesions.
Krishna and colleagues found that the in vivo nCLE patterns were identical to the ex vivo pCLE patterns for all the major neoplastic pancreatic cystic lesions, and that both findings correlated with surgical histopathology.
“The evaluation of PCLs continues to pose a challenge. In uncertain clinical situations, a composite approach including clinical features, imaging characteristics, cyst fluid [carcinoembryonic antigen], cytological examination, and nCLE is necessary,” they concluded. “The correlation of histopathology and the reproducibility of in vivo and ex vivo CLE imaging patterns supports the application of EUS-nCLE as an imaging biomarker in the diagnosis of PCLs.”
The researchers noted that further research is required to confirm the effectiveness of EUS-nCLE alone or combined with cyst fluid molecular markers. – by Adam Leitenberger
Disclosures: The researchers report no relevant financial disclosures.